320 related articles for article (PubMed ID: 33241036)
1. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.
Chen J; Hu X; Li Q; Dai W; Cheng X; Huang W; Yu W; Chen M; Guo Y; Yuan G
Ann Transl Med; 2020 Sep; 8(18):1187. PubMed ID: 33241036
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.
Liu H; Qin X; Xu Z; Wu M; Lu T; Zhou S; Yao N; Liu S; Shao Y; Han Z
Front Genet; 2022; 13():1000448. PubMed ID: 36160021
[No Abstract] [Full Text] [Related]
3. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.
Li T; Guo J; Liu Y; Du Z; Guo Z; Fan Y; Cheng L; Zhang Y; Gao X; Zhao Y; He X; Wu W; Gao N; Wu Y; Li J; Zhang Y; Kang W; Cai Z; Wang W; Li X; Zan Y; Nguyen MH; Ji F
Cancer Immunol Immunother; 2023 Jul; 72(7):2137-2149. PubMed ID: 36840762
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.
You R; Xu Q; Wang Q; Zhang Q; Zhou W; Cao C; Huang X; Ji H; Lv P; Jiang H; Lu Y; Jin Y; Li Y; Cheng L; Wang W; Xu H; Zhu X; Yin G
Front Oncol; 2022; 12():816198. PubMed ID: 35982962
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
[TBL] [Abstract][Full Text] [Related]
8. Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study.
Zheng X; Tao G; Sun S; Jin X; Chen Y; Zhang Y; Sun J; Huang P
Ann Transl Med; 2022 Feb; 10(4):183. PubMed ID: 35280395
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.
Huang N; Zhao C; Hu X; Zhang C; Xiong F; Huang W; Da L; Shen Y; Wu H
Transl Cancer Res; 2022 Jan; 11(1):252-261. PubMed ID: 35261901
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study.
Zhang CS; Zeng ZM; Zhuo MY; Luo JR; Zhuang XH; Xu JN; Zeng J; Ma J; Lin HF
Oncologist; 2023 Dec; 28(12):e1239-e1247. PubMed ID: 37329569
[TBL] [Abstract][Full Text] [Related]
12. Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib.
Shen Y; Wang H; Wei J; Li W
Onco Targets Ther; 2021; 14():5019-5026. PubMed ID: 34675546
[TBL] [Abstract][Full Text] [Related]
13. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
15. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis.
Zhao M; Shao T; Ren Y; Zhou C; Tang W
Front Pharmacol; 2022; 13():910656. PubMed ID: 36249794
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
17. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
Teng Y; Ding X; Li W; Sun W; Chen J
Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
[No Abstract] [Full Text] [Related]
20. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
Front Oncol; 2021; 11():835889. PubMed ID: 35174073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
